An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension

Journal of Clinical Psychiatry

Volumn 67, Issue 5, 2006, Pages 696-702

  Wilens, Timothy E ^a   Zusman, Randall M ^a   Hammerness, Paul G ^a   Podolski, Amy ^a   Whitley, Julia ^a   Spencer, Thomas J ^a   Gignac, Martin ^b   Biederman, Joseph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Institut Philippe Pinel de Montreal   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL STIMULANT AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; ANAMNESIS; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG RELEASE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MAXIMUM PERMISSIBLE DOSE; NERVOUSNESS; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAL SIGN; XEROSTOMIA;

EID: 33745373543     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0502     Document Type: Article

References (41)

1. Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998;59(suppl 7):4-16
2. Weiss G, Hechtman L, Milroy T, et al. Psychiatric status of hyperactives as adults: a controlled prospective 15 year followup of 63 hyperactive children. J Am Acad Child Psychiatry 1985;24:211-220
3. Wilens T, Faraone SV, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA 2004;292:619-623
4. Bauermeister JJ, Canino G, Bird H. Epidemiology of disruptive behavior disorders. Child Adolesc Psychiatr Clin N Am 1994;3:177-194
5. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2:104-113
6. Murphy K, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Arten Disord 1996;1:147-161
7. Barkley RA, Fischer M, Smallish L, et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry 2004;45:195-211
8. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
9. Alpert J, Maddocks A, Nierenberg A, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res 1996;62:213-219
10. Levin FR, Evans SM, Kleber HD. Practical guidelines for the treatment of substance abusers with adult attention-deficit hyperactivity disorder. Psychiatr Serv 1999;50:1001-1003
11. Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk and treatment issues. Psychiatr Clin North Am 2004;27:283-301
12. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993;150:1792-1798
13. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry 2004;161:1948-1956
14. Wilens T. Drug therapy for adults with attention-deficit hyperactivity disorder. Drugs 2003;63:2395-2411
15. Goldman L, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998;279:1100-1107
16. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(suppl 2):26S-49S
17. Wilens TE, Dodson W. A clinical perspective of attention-deficit/ hyperactivity disorder into adulthood. J Clin Psychiatry 2004;65:1301-1313
18. Wender PH, Reimherr FW, Wood DR. Attention deficit disorder ("minimal brain dysfunction") in adults: a replication study of diagnosis and drug treatment. Arch Gen Psychiatry 1981;38:449-456
19. Spencer T, Wilens TE, Biederman J, et al. A double blind, crossover comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-443
20. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58:775-782
21. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158:282-288
22. Wilens T, Hammerness P, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2005;66:253-259
23. Gutgesell H, Atkins D, Barst R, et al. AHA scientific statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 1999;38:1047-1050
24. Wilens T, Biederman J, Prince J, et al. Six-week, double blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996;153:1147-1153
25. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-120
26. National Institutes of Health. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, Md: National Heart, Lung, and Blood Institute; 1997
27. Ratey JJ, Greenberg MS, Lindem KJ. Combination of treatments for attention deficit hyperactivity disorder in adults. J Nerv Ment Dis 1991;179:699-701
28. First M, Spitzer R, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Press; 1997
29. Ambrosini PJ. Historical development and present status of the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS). J Am Acad Child Adolesc Psychiatry 2000;39:49-58
30. Weisler RH, Biederman J, Chrisman AK, et al. Long-term safety and efficacy of once-daily Adderall-XR in adults with ADHD. In: New Research Abstracts of the 156th Annual Meeting of the American Psychiatric Association; May 17-22,2003; San Francisco, Calif. 242:NR647
31. Weisler RH. Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD. Expert Opin Pharmacother 2005;6:1003-1018
32. Adler L. Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:187-202
33. National Institute of Mental Health. Clinical Global Impression (CGI). Psychopharmacol Bull 1985;21:839-844
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
35. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
36. Magill MK, Gunning K, Saffel-Shrier S, et al. New developments in the management of hypertension. Am Fam Physician 2003;68:853-858
37. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22
38. Stata Corporation. Stata User's Guide, Release 7.0. College Station, Tex: Stata Corporation; 2001
39. Wilens TE, Spencer T. The stimulants revisited. Child Adolesc Psychiatr Clin N Am 2000;9:573-603
40. Safer DJ. The relative cardiovascular safety of psychostimulants used to treat attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 1992;2:279-290
41. Wilens TE, Biederman J, Lerner M, et al. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004;24:36-41